donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > QURE uniQure NV > Main Composition
QURE uniQure NV
19.110
-0.430-2.20%
Post Mkt Price
18.750
-0.36-1.88%
All
YOY
Do not show
Business Unit:USD
nameYOYOperating income%
License revenue--517.4M98.74%
Collaboration revenue--6.6M1.26%
Region Unit:USD
nameYOYOperating income%
United States--7.28M100.00%
Company Overview More
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
CEO: Kapusta, Matthew Craig
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...